R&D-driven

Takeda Completes Sale of Select OTC and Non-Core Assets to Orifarm

OSAKA, Japan–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of…

Read More »